Home
User Guide
What's in a MalaCard Search Guide Our Sources
Analysis Tools
GeneCards GeneAnalytics GeneAlaCart PathCards VarElect TGex
News and Views Disease Lists/Categories
About
About MalaCards Our Publications Weizmann Institute LifeMap Discovery® Terms of Use MalaCards Team
MCID: LMY004
MIFTS: 58

Leiomyosarcoma

Categories: Cancer diseases, Muscle diseases, Rare diseases
Genes Variations Tissues Related diseases Publications Pathways Drugs
Sources

Aliases & Classifications for Leiomyosarcoma

About this section

MalaCards integrated aliases for Leiomyosarcoma:

Name: Leiomyosarcoma 12 76 53 59 55 6 44 15 73
Leiomyosarcomas 12

Classifications:

MalaCards categories:
Global: Rare diseases Cancer diseases
Anatomical: Muscle diseases
See all MalaCards categories (disease lists)
ICD10: 34


External Ids:

Disease Ontology 12 DOID:1967
MeSH 44 D007890
NCIt 50 C3158
SNOMED-CT 68 51549004
Orphanet 59 ORPHA64720
MESH via Orphanet 45 D007890
UMLS via Orphanet 74 C0023269
ICD10 via Orphanet 34 C49.9
UMLS 73 C0023269
Sources

Summaries for Leiomyosarcoma

About this section
NIH Rare Diseases : 53 Leiomyosarcoma is a rare cancerous tumor that consists of smooth (involuntary) muscle cells. Leiomyosarcoma is a type of sarcoma. It spreads through the blood stream and can affect the lungs, liver, blood vessels, or any other soft tissue in the body. The exact cause of leiomyosarcoma is not known, although genetic and environmental factors appear to be involved. It is most often found in the uterus or abdomen.

MalaCards based summary : Leiomyosarcoma, also known as leiomyosarcomas, is related to myxoid leiomyosarcoma and epithelioid leiomyosarcoma. An important gene associated with Leiomyosarcoma is KIT (KIT Proto-Oncogene Receptor Tyrosine Kinase), and among its related pathways/superpathways are ERK Signaling and Phospholipase-C Pathway. The drugs Oxaliplatin and Cola have been mentioned in the context of this disorder. Affiliated tissues include uterus, smooth muscle and liver, and related phenotypes are Decreased viability in esophageal squamous lineage and cellular

Disease Ontology : 12 A malignant smooth muscle cancer that can arise almost anywhere in the body, but is most common in the uterus, abdomen, or pelvis.

Wikipedia : 76 Leiomyosarcoma, also referred to as LMS, is a malignant (cancerous) smooth muscle tumor. A benign tumor... more...

Sources

Related Diseases for Leiomyosarcoma

About this section

Diseases in the Leiomyosarcoma family:

Inflammatory Leiomyosarcoma

Diseases related to Leiomyosarcoma via text searches within MalaCards or GeneCards Suite gene sharing:

(show top 50) (show all 459)
# Related Disease Score Top Affiliating Genes
1 myxoid leiomyosarcoma 34.0 ACTC1 PGR
2 epithelioid leiomyosarcoma 33.7 ACTC1 DES ENO2 VIM
3 cutaneous leiomyosarcoma 33.5 ACTC1 DES FH VIM
4 small intestine leiomyosarcoma 33.4 IGF2 KIT
5 gastric leiomyosarcoma 33.0 ENO2 IGF2 KIT PDGFRA
6 gastrointestinal stromal tumor 30.7 ACTC1 DES ENO2 IGF2 KIT PDGFRA
7 sarcoma 30.5 CDK4 KIT MDM2 TP53 WT1
8 fibrous histiocytoma 30.5 ACTC1 DES S100B VIM
9 uterine carcinosarcoma 30.3 KIT PGR TP53
10 histiocytoma 30.3 KIT MB MDM2 TP53
11 smooth muscle tumor 30.3 ACTC1 DES KIT PGR VIM
12 leiomyomatosis 30.3 FH MED12 PGR
13 adenocarcinoma 30.3 CDK4 KIT PDGFRB TP53
14 carcinosarcoma 30.2 ACTC1 DES KIT PGR TP53 VIM
15 sarcoma, synovial 30.2 DES KIT MDM2 VIM
16 liposarcoma 30.2 CDK4 DES MB MDM2 TP53 VIM
17 malignant fibroxanthoma 30.1 ACTC1 CDK4 DES MDM2 S100B VIM
18 leiomyoma 30.1 ACTC1 DES FH IGF2 KIT MED12
19 giant cell tumor 30.1 ACTC1 DES VIM
20 bizarre leiomyoma 30.0 ACTC1 MED12 PGR
21 spindle cell sarcoma 30.0 ACTC1 DES MDM2 S100B VIM
22 mesenchymoma 29.9 DES MB MDM2
23 neurofibroma 29.9 KIT PDGFRA S100B
24 endometrial stromal sarcoma 29.8 ACTC1 DES KIT MB PDGFRB PGR
25 endosalpingiosis 29.8 PGR WT1
26 benign breast phyllodes tumor 29.8 KIT PGR VIM
27 syringocystadenoma papilliferum 29.8 DES S100B VIM
28 malignant giant cell tumor 29.8 ACTC1 S100B TP53
29 angiomyoma 29.8 ENO2 KIT MB
30 myxoid liposarcoma 29.7 CDK4 MDM2 TP53
31 glomus tumor 29.7 ACTC1 DES ENO2 TP53 VIM
32 cutaneous fibrous histiocytoma 29.7 ACTC1 DES S100B VIM
33 desmoid tumor 29.6 KIT PDGFRA PDGFRB
34 neurilemmoma 29.6 DES ENO2 KIT PDGFRA S100B VIM
35 epulis 29.6 DES ENO2 PGR VIM
36 teratoma 29.6 ACTC1 ENO2 KIT TP53
37 dedifferentiated liposarcoma 29.5 ACTC1 CDK4 DES MB MDM2 TP53
38 diffuse peritoneal leiomyomatosis 29.5 KIT MED12 PGR WT1
39 pleomorphic adenoma 29.5 ACTC1 MDM2 S100B TP53 VIM
40 embryonal rhabdomyosarcoma 29.4 DES IGF2 MB MYOG
41 renal cell carcinoma, nonpapillary 29.4 FH KIT PDGFRB S100A1 VIM WT1
42 uterine sarcoma 29.4 DES KIT MB MDM2 PDGFRB WT1
43 glioblastoma multiforme 29.2 CDK4 MDM2 PDGFRA PDGFRB TP53
44 glioblastoma 29.2 CDK4 MDM2 PDGFRA PDGFRB TP53
45 malignant mesenchymoma 29.2 CDK4 DES KIT MB MDM2 MYOG
46 dermatofibrosarcoma protuberans 29.0 ACTC1 DES KIT PDGFRA PDGFRB S100B
47 malignant peripheral nerve sheath tumor 29.0 ACTC1 CDK4 KIT MDM2 PDGFRA S100A1
48 rhabdomyosarcoma 28.3 ACTC1 CDK4 DES ENO2 IGF2 MB
49 pulmonary artery leiomyosarcoma 12.4
50 lung leiomyosarcoma 12.4

Graphical network of the top 20 diseases related to Leiomyosarcoma:



Diseases related to Leiomyosarcoma
Sources

Symptoms & Phenotypes for Leiomyosarcoma

About this section

GenomeRNAi Phenotypes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

26
# Description GenomeRNAi Source Accession Score Top Affiliating Genes
1 Decreased viability in esophageal squamous lineage GR00235-A 9.32 CAPN6 DES KIT MB MED12 PDGFRA

MGI Mouse Phenotypes related to Leiomyosarcoma:

46 (show all 22)
# Description MGI Source Accession Score Top Affiliating Genes
1 cellular MP:0005384 10.52 ACTC1 CDK4 DES ENO2 FH IGF2
2 cardiovascular system MP:0005385 10.47 ACTC1 CDK4 DES IGF2 KIT MB
3 behavior/neurological MP:0005386 10.45 CDK4 DES ENO2 IGF2 KIT MDM2
4 homeostasis/metabolism MP:0005376 10.45 ACTC1 CDK4 DES FH IGF2 KIT
5 growth/size/body region MP:0005378 10.39 ACTC1 CAPN6 CDK4 ENO2 IGF2 KIT
6 embryo MP:0005380 10.38 CDK4 IGF2 KIT MB MDM2 MED12
7 mortality/aging MP:0010768 10.38 ACTC1 CDK4 DES FH IGF2 KIT
8 muscle MP:0005369 10.36 ACTC1 CAPN6 CDK4 DES IGF2 KIT
9 hematopoietic system MP:0005397 10.28 CDK4 IGF2 KIT MB MDM2 PDGFRA
10 craniofacial MP:0005382 10.24 CAPN6 ENO2 IGF2 KIT MDM2 MED12
11 endocrine/exocrine gland MP:0005379 10.21 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
12 integument MP:0010771 10.21 CDK4 IGF2 KIT MDM2 MYOG PDGFRA
13 digestive/alimentary MP:0005381 10.18 CAPN6 CDK4 IGF2 KIT MDM2 PDGFRA
14 normal MP:0002873 10.18 ACTC1 CDK4 KIT MDM2 MED12 MYOG
15 limbs/digits/tail MP:0005371 10.1 IGF2 KIT MDM2 MED12 PDGFRA PDGFRB
16 no phenotypic analysis MP:0003012 10.01 IGF2 KIT MDM2 MYOG PDGFRA PGR
17 neoplasm MP:0002006 9.98 CDK4 KIT MDM2 PDGFRA PGR TP53
18 renal/urinary system MP:0005367 9.91 CDK4 FH IGF2 KIT MDM2 PDGFRA
19 reproductive system MP:0005389 9.85 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
20 pigmentation MP:0001186 9.72 CDK4 KIT MDM2 PDGFRA TP53
21 respiratory system MP:0005388 9.65 ENO2 IGF2 KIT MB MYOG PDGFRA
22 skeleton MP:0005390 9.28 IGF2 KIT MDM2 MED12 MYOG PDGFRA
Sources

Drugs & Therapeutics for Leiomyosarcoma

About this section

Drugs for Leiomyosarcoma (from DrugBank, HMDB, Dgidb, PharmGKB, IUPHAR, NovoSeek, BitterDB):

(show top 50) (show all 183)
# Name Status Phase Clinical Trials Cas Number PubChem Id
1
Oxaliplatin Approved, Investigational Phase 4,Phase 1 61825-94-3 43805 6857599 5310940 9887054
2 Cola Phase 4,Phase 3,Phase 1,Phase 2,Not Applicable
3 Liver Extracts Phase 4,Phase 3,Phase 1,Not Applicable
4
Mechlorethamine Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 51-75-2 4033
5
Ifosfamide Approved Phase 3,Phase 2,Phase 1,Not Applicable 3778-73-2 3690
6
Doxorubicin Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 23214-92-8 31703
7
Dacarbazine Approved, Investigational Phase 3,Phase 2 4342-03-4 5351166
8
Docetaxel Approved, Investigational Phase 3,Phase 2,Phase 1,Not Applicable 114977-28-5 148124
9
Gemcitabine Approved Phase 3,Phase 2,Phase 1,Not Applicable 95058-81-4 60750
10
Trabectedin Approved, Investigational Phase 3,Phase 2,Phase 1 114899-77-3 108150
11
Lenograstim Approved, Investigational Phase 3,Phase 2 135968-09-1
12
Etoposide Approved Phase 3,Phase 2 33419-42-0 36462
13
Carboplatin Approved Phase 3,Phase 2 41575-94-4 10339178 38904 498142
14
Dactinomycin Approved, Investigational Phase 3,Phase 2 50-76-0 457193 2019
15
Cyclophosphamide Approved, Investigational Phase 3,Phase 2 6055-19-2, 50-18-0 2907
16
Vincristine Approved, Investigational Phase 3,Phase 2 57-22-7, 2068-78-2 5978
17
Epirubicin Approved Phase 3,Phase 2 56420-45-2 41867
18
Fentanyl Approved, Illicit, Investigational, Vet_approved Phase 3 437-38-7 3345
19
Ondansetron Approved Phase 3 99614-02-5 4595
20
Dexamethasone Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 50-02-2 5743
21
Dexamethasone acetate Approved, Investigational, Vet_approved Phase 3,Phase 2,Not Applicable 1177-87-3
22
Bevacizumab Approved, Investigational Phase 3,Phase 2 216974-75-3
23 Olaratumab Approved, Investigational Phase 3,Phase 2,Phase 1 1024603-93-7
24
Histamine Approved, Investigational Phase 3 51-45-6, 75614-87-8 774
25
Cyproheptadine Approved Phase 3 129-03-3 2913
26
Doxil Approved June 1999 Phase 3,Phase 2,Phase 1,Not Applicable 31703
27 Pancreatic Polypeptide Investigational Phase 3,Phase 1 59763-91-6
28
Isophosphamide mustard Phase 3,Phase 2,Phase 1,Not Applicable 0
29 Anti-Bacterial Agents Phase 3,Phase 2,Phase 1,Not Applicable
30 Antineoplastic Agents, Alkylating Phase 3,Phase 2,Phase 1,Not Applicable
31 Antibiotics, Antitubercular Phase 3,Phase 2,Phase 1,Not Applicable
32 Alkylating Agents Phase 3,Phase 2,Phase 1,Not Applicable
33 Topoisomerase Inhibitors Phase 3,Phase 2,Phase 1,Not Applicable
34 Immunologic Factors Phase 3,Phase 2,Phase 1,Not Applicable
35 Anti-Infective Agents Phase 3,Phase 2,Phase 1,Not Applicable
36 Antimitotic Agents Phase 3,Phase 2,Phase 1,Not Applicable
37 Immunosuppressive Agents Phase 3,Phase 2,Phase 1,Not Applicable
38 Antiviral Agents Phase 3,Phase 2,Phase 1,Not Applicable
39 Antimetabolites Phase 3,Phase 2,Phase 1,Not Applicable
40 Antimetabolites, Antineoplastic Phase 3,Phase 2,Phase 1,Not Applicable
41 Angiogenesis Modulating Agents Phase 3,Phase 2,Phase 1
42 Angiogenesis Inhibitors Phase 3,Phase 2,Phase 1
43 Pharmaceutical Solutions Phase 3,Not Applicable
44 Etoposide phosphate Phase 3,Phase 2
45 Antineoplastic Agents, Phytogenic Phase 3,Phase 2,Phase 1
46 Antirheumatic Agents Phase 3,Phase 2,Phase 1
47 Nucleic Acid Synthesis Inhibitors Phase 3,Phase 2
48 Central Nervous System Depressants Phase 3
49 Adjuvants, Anesthesia Phase 3
50 Anesthetics, Intravenous Phase 3

Interventional clinical trials:

(show top 50) (show all 162)
# Name Status NCT ID Phase Drugs
1 Relationship Between Platinum Levels in the Blood and Neurotoxicity in Patients Who Are Receiving Oxaliplatin for Gastrointestinal Cancer Unknown status NCT00274885 Phase 4 oxaliplatin
2 Surgery With or Without Radiation Therapy in Untreated Nonmetastatic Retroperitoneal Sarcoma Unknown status NCT01344018 Phase 3
3 Ifosfamide and Doxorubicin, Radiation Therapy, and/or Surgery in Treating Young Patients With Localized Soft Tissue Sarcoma Unknown status NCT00334854 Phase 3 doxorubicin hydrochloride;ifosfamide
4 A Study of Trabectedin (YONDELIS) in Patients With Locally Advanced or Metastatic Liposarcoma or Leiomyosarcoma Completed NCT01692678 Phase 3 Trabectedin;Dacarbazine
5 A Study of Trabectedin or Dacarbazine for the Treatment of Patients With Advanced Liposarcoma or Leiomyosarcoma Completed NCT01343277 Phase 3 Trabectedin;Dacarbazine
6 Observation, Radiation Therapy, Combination Chemotherapy, and/or Surgery in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00346164 Phase 3 doxorubicin hydrochloride;ifosfamide
7 Radiation Therapy or No Further Treatment Following Surgery in Treating Patients With Cancer of the Uterus Completed NCT00002459 Phase 3
8 Surgery With or Without Combination Chemotherapy in Treating Patients With Lung Metastases From Soft Tissue Sarcoma Completed NCT00002764 Phase 3 doxorubicin hydrochloride;ifosfamide
9 Surgery With or Without Chemotherapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00002641 Phase 3 doxorubicin hydrochloride;ifosfamide;isolated perfusion
10 Ifosfamide or Doxorubicin in Treating Patients With Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00003212 Phase 3 doxorubicin hydrochloride;ifosfamide
11 Combination Chemotherapy With or Without Hyperthermia Therapy in Treating Patients With Soft Tissue Sarcoma Completed NCT00003052 Phase 3 doxorubicin hydrochloride;etoposide;ifosfamide
12 Doxorubicin With or Without Ifosfamide and Pegfilgrastim in Treating Patients With Locally Advanced or Metastatic Soft Tissue Sarcoma Completed NCT00061984 Phase 3 doxorubicin hydrochloride;ifosfamide
13 Surgery With or Without Radiation Therapy in Treating Patients With Primary Soft Tissue Sarcoma of the Retroperitoneum or Pelvis Completed NCT00091351 Phase 3
14 Surgery Followed by Chemotherapy in Treating Young Patients With Soft Tissue Sarcoma Completed NCT00002898 Phase 3 carboplatin;cyclophosphamide;epirubicin hydrochloride;etoposide;ifosfamide;vincristine sulfate
15 Fentanyl Sublingual Spray in Treating Patients With Breakthrough Cancer Pain Completed NCT00538850 Phase 3 Fentanyl sublingual spray;Placebo
16 Ondansetron With or Without Dexamethasone to Prevent Vomiting in Patients Receiving Radiation Therapy to the Upper Abdomen Completed NCT00016380 Phase 3 dexamethasone;ondansetron
17 Pazopanib Versus Placebo in Patients With Soft Tissue Sarcoma Whose Disease Has Progressed During or Following Prior Therapy Completed NCT00753688 Phase 3 PAZOPANIB;Placebo
18 A Phase III Trial of Anlotinib in Metastatic or Advanced Alveolar Soft Part Sarcoma, Leiomyosarcoma and Synovial Sarcoma Recruiting NCT03016819 Phase 3 AL 3818;Dacarbazine
19 Localized High-Risk Soft Tissue Sarcomas Of The Extremities And Trunk Wall In Adults: An Integrating Approach Comprising Standard Vs Histotype-Tailored Neoadjuvant Chemotherapy Recruiting NCT01710176 Phase 3 epirubicin 60 mg/m2/day (days 1, 2) and ifosfamide 3 g/m2/day (days 1, 2, 3);gemcitabine 900 mg/m2 (days 1 and 8) and docetaxel 75 mg/m2 (day 8);trabectedin 1.3 mg/m2;high-dose ifosfamide 14 g/m2, given in in 14 days;etoposide 150 mg/m2/day (days 1, 2, 3) and ifosfamide 3g/m2/day (days 1, 2, 3);gemcitabine 1800 mg/m2 (day 1) and dacarbazine 500 mg/m2 (day 1)
20 Gemcitabine Hydrochloride and Docetaxel Followed by Doxorubicin Hydrochloride or Observation in Treating Patients With High-Risk Uterine Leiomyosarcoma Previously Removed by Surgery Active, not recruiting NCT01533207 Phase 3 Docetaxel;Doxorubicin Hydrochloride;Gemcitabine Hydrochloride
21 A Study of Doxorubicin Plus Olaratumab (LY3012207) in Participants With Advanced or Metastatic Soft Tissue Sarcoma Active, not recruiting NCT02451943 Phase 3 Olaratumab;Doxorubicin;Placebo
22 Randomised Trial of Volume of Post-operative Radiotherapy Given to Adult Patients With eXtremity Soft Tissue Sarcoma Active, not recruiting NCT00423618 Phase 3
23 Study Comparing Efficacy of Doxorubicin With Trabectedin Followed by Trabectedin Versus Doxorubicine in Patients With Leiomyosarcoma Not yet recruiting NCT02997358 Phase 3 Doxorubicin;Trabectedin
24 Study on Leiomyosarcoma, Liposarcomas and Synovial Sarcoma With Trabectedin Not yet recruiting NCT03773510 Phase 3 Trabectedin discontinuation;Trabectedin continuation
25 Radiation Therapy With or Without Combination Chemotherapy or Pazopanib Hydrochloride Before Surgery in Treating Patients With Newly Diagnosed Non-rhabdomyosarcoma Soft Tissue Sarcomas That Can Be Removed by Surgery Suspended NCT02180867 Phase 2, Phase 3 Doxorubicin Hydrochloride;Ifosfamide;Pazopanib Hydrochloride
26 Gemcitabine Hydrochloride and Docetaxel With or Without Bevacizumab in Treating Patients With Advanced or Recurrent Uterine Leiomyosarcoma Terminated NCT01012297 Phase 3 Docetaxel;Gemcitabine Hydrochloride
27 Cyproheptadine in Preventing Weight Loss in Children Receiving Chemotherapy for Cancer Terminated NCT01132547 Phase 3 cyproheptadine hydrochloride
28 Doxorubicin Hydrochloride or Trabectedin in Treating Patients With Previously Untreated Advanced or Metastatic Soft Tissue Sarcoma Terminated NCT01189253 Phase 2, Phase 3 doxorubicin hydrochloride;trabectedin
29 Pazopanib vs. Pazopanib Plus Gemcitabine in Patients With Relapsed or Metastatic Uterine Leiomyosarcomas or Uterine Carcinosarcomas: a Multi-center, Randomized Phase-II Clinical Trial of the NOGGO and AGO - PazoDoble - Unknown status NCT02203760 Phase 2 Pazopanib plus Gemcitabine;Pazopanib
30 Efficacy of Gemcitabine With Pazopanib as Second Line Treatment in Patients With Metastatic or Relapsed Uterine or Soft Tissue Leiomyosarcomas Unknown status NCT01442662 Phase 2 pazopanib + gemcitabine
31 Trial of Nilotinib and Adriamycin as Treatment in Liposarcomas and Leiomyosarcomas of Retroperitoneum Unknown status NCT02587169 Phase 1, Phase 2 Nilotinib-adriamycin
32 Temozolomide and Thalidomide in Treating Patients With Metastatic, Locally Advanced, or Unresectable Leiomyosarcoma Unknown status NCT00033709 Phase 2 temozolomide;thalidomide
33 Temozolomide in Treating Patients With Advanced Soft Tissue Sarcoma Unknown status NCT00003718 Phase 2 temozolomide
34 Brostallicin or Doxorubicin as First-Line Therapy in Treating Patients With Relapsed, Refractory, or Metastatic Soft Tissue Sarcoma Unknown status NCT00410462 Phase 2 brostallicin;doxorubicin hydrochloride
35 Activity of Trabectedin or Gemcitabine + Docetaxel in Uterine Leiomyosarcoma Completed NCT02249702 Phase 2 gemcitabine + docetaxel;trabectedin
36 Study of Doxorubicin and Trabectedin in First Line Treatment on Patients With Metastatic Leiomyosarcoma Completed NCT02131480 Phase 2 Doxorubicin;Trabectedin
37 SARC018: A Study of Mocetinostat and Gemcitabine in Patients With Metastatic Leiomyosarcoma Completed NCT02303262 Phase 2 Mocetinostat;Gemcitabine
38 Letrozole in Women With Advanced Estrogen/Progesterone Receptor Positive Uterine Leiomyosarcoma Completed NCT00856050 Phase 2 letrozole
39 Nivolumab Alone or in Combination With Ipilimumab in Treating Patients With Advanced Uterine Leiomyosarcoma Completed NCT02428192 Phase 2
40 Alisertib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT01637961 Phase 2 Alisertib
41 Adjuvant Chemotherapy for High Risk Uterine Leiomyosarcoma Completed NCT00282087 Phase 2 gemcitabine, docetaxel, doxorubicin
42 Ixabepilone in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Previously Treated With Chemotherapy Completed NCT01220609 Phase 2 Ixabepilone
43 Sunitinib in Treating Patients With Recurrent or Persistent Leiomyosarcoma of the Uterus Completed NCT00378911 Phase 2 sunitinib malate
44 Trabectedin in Treating Patients With Advanced, Persistent, or Recurrent Leiomyosarcoma of the Uterus Completed NCT00379145 Phase 2 trabectedin
45 Safety and Efficacy Study of ARQ 501 in Adult Patients With Leiomyosarcoma Completed NCT00310518 Phase 2 ARQ 501
46 Docetaxel, Gemcitabine, and Filgrastim (G-CSF) or Pegfilgrastim in Treating Patients With Advanced, Persistent, or Recurrent Uterine Leiomyosarcoma Completed NCT00101127 Phase 2 docetaxel;gemcitabine hydrochloride
47 Gemcitabine With or Without Docetaxel as Second-Line Therapy in Treating Patients With Metastatic or Relapsed, Unresectable Uterine or Soft Tissue Leiomyosarcoma Completed NCT00227669 Phase 2 docetaxel;gemcitabine hydrochloride
48 Gemcitabine, Docetaxel, and Filgrastim in Treating Patients With Recurrent or Persistent Leiomyosarcoma or Soft Tissue Sarcoma Completed NCT00004066 Phase 2 docetaxel;gemcitabine hydrochloride
49 A Study to Assess Treatment With 2 Different Dosing Schedules of Trabectidin Administered to Patients With Advanced Cancer Completed NCT00060944 Phase 2 Yondelis;Yondelis;Dexamethasone;Dexamethasone
50 Thalidomide in Treating Patients With Recurrent or Persistent Cancer of the Uterus Completed NCT00025220 Phase 2 Thalidomide

Search NIH Clinical Center for Leiomyosarcoma

Cochrane evidence based reviews: leiomyosarcoma

Sources

Genetic Tests for Leiomyosarcoma

About this section
Sources

Anatomical Context for Leiomyosarcoma

About this section

MalaCards organs/tissues related to Leiomyosarcoma:

41
Uterus, Smooth Muscle, Liver, Lung, Breast, Bone, Prostate
Sources

Publications for Leiomyosarcoma

About this section

Articles related to Leiomyosarcoma:

(show top 50) (show all 2106)
# Title Authors Year
1
A randomized phase II study of letrozole vs. observation in patients with newly diagnosed uterine leiomyosarcoma (uLMS). ( 30519622 )
2019
2
Recurrence of Primary Vascular Leiomyosarcoma Five Years after Initial Diagnosis in the Lower Extremity. ( 29971175 )
2018
3
Primary leiomyosarcoma in the colon: A case report. ( 29443772 )
2018
4
Radiation-induced leiomyosarcoma of the rectum after cervical cancer treatment. ( 29439826 )
2018
5
Leiomyosarcoma of the stomach with metastasis to the liver: a case report with review of the literature. ( 29379638 )
2018
6
Denosumab as a potential therapeutic option for leiomyosarcoma with osteoclast-like giant cells: A case report. ( 29387393 )
2018
7
Delayed diagnosis of dermal leiomyosarcoma mimicking keloid scar. ( 29374640 )
2018
8
Coexistence of Cervical Leiomyosarcoma and Gastric-Type Adenocarcinoma In Situ with Extensive Extension to the Endometrium and Fallopian Tube. ( 29670794 )
2018
9
Cancer-testis antigens are predominantly expressed in uterine leiomyosarcoma compared with non-uterine leiomyosarcoma. ( 29399140 )
2018
10
Leiomyosarcoma of the great saphenous vein (vena saphena magna) with granular cell change: Report of a superficial neoplasm. ( 29068077 )
2018
11
Options for Adjuvant Therapy for Uterine Leiomyosarcoma. ( 29417238 )
2018
12
Role of bevacizumab in uterine leiomyosarcoma. ( 29759566 )
2018
13
Partial cystectomy for a primary locally advanced leiomyosarcoma of the bladder: a case report and review of the literature. ( 29744079 )
2018
14
Treatment with epigenetic agents profoundly inhibits tumor growth in leiomyosarcoma. ( 29721210 )
2018
15
Primary leiomyosarcoma of the fallopian tube: Three case reports and review of the literature. ( 29880185 )
2018
16
Neuropilin 1 in uterine leiomyosarcoma. Clinical and pathological analysis. ( 29411340 )
2018
17
Primary pulmonary leiomyosarcoma: A population-based study. ( 29413053 )
2018
18
A rare primary leiomyosarcoma of the parotid gland: A case report and literature review. ( 29395283 )
2018
19
Establishment and characterization of patient-derived xenograft and its cell line of primary leiomyosarcoma of bone. ( 29845452 )
2018
20
Review of the literature laparoscopic surgery for metastatic hepatic leiomyosarcoma associated with smooth muscle tumor of uncertain malignant potential: Case report. ( 29713398 )
2018
21
Resection of a Perirectal Leiomyosarcoma via a Posterior Transcoccygeal Approach. ( 29981026 )
2018
22
Pazopanib-mediated Long-term Disease Stabilization after Local Recurrence and Distant Metastasis of Primary Intracranial Leiomyosarcoma: A Case Report on the Efficacy of Pazopanib as a Salvage Therapy. ( 29354331 )
2018
23
Pulmonary artery leiomyosarcoma: A clinical dilemma. ( 29487255 )
2018
24
Metastatic leiomyosarcoma presenting as a lung mass with left atrial extension: case report and anesthetic management. ( 29403281 )
2018
25
Anterior mediastinal leiomyosarcoma mimicking thymoma: A case report. ( 29924013 )
2018
26
Long-Term Progression-Free Survival in a Patient with Metastatic Leiomyosarcoma of the Inguinal Region Treated with Trabectedin. ( 29805376 )
2018
27
Primary breast leiomyosarcoma with metastases to the lung in a young adult: Case report and literature review. ( 29705677 )
2018
28
Posterior reversible encephalopathy syndrome (PRES) in mesenteric leiomyosarcoma: A case report. ( 29980031 )
2018
29
Primary Leiomyosarcoma of the Colon: A Report of Two Cases, Review of the Literature, and Association with Immunosuppression for IBD and Rheumatoid Arthritis. ( 29780656 )
2018
30
Diagnosis and management of rare inferior vena cava leiomyosarcoma guided by a novel minimally invasive vascular biopsy technique. ( 29411530 )
2018
31
Organ preservation in leiomyosarcoma bladder: Case report and review of literature. ( 29719342 )
2018
32
A Case Report of Metastatic Primary Thyroid Leiomyosarcoma Treated with Pazopanib. ( 29431311 )
2018
33
The prevalence of occult leiomyosarcoma in women undergoing presumed fibroid surgery and outcomes after morcellation. ( 29251674 )
2018
34
Functionality of the Tumor Suppressor <i>microRNA-1</i> in Malignant Tissue and Cell Line Cells of Uterine Leiomyosarcoma. ( 29491084 )
2018
35
Malignant transformation of uterine leiomyoma to myxoid leiomyosarcoma after morcellation associated with <i>ALK</i> rearrangement and loss of 14q. ( 29963223 )
2018
36
Primary intracranial leiomyosarcoma with intra-tumoral hemorrhage: Case report and review of literature. ( 29753901 )
2018
37
Molecular biomarkers for uterine leiomyosarcoma and endometrial stromal sarcoma. ( 29660202 )
2018
38
Multimodality management of leiomyosarcoma of the cervix. ( 29743950 )
2018
39
Cutaneous leiomyosarcoma on the face. ( 29723357 )
2018
40
Identification of key genes and pathways in uterine leiomyosarcoma through bioinformatics analysis. ( 29844831 )
2018
41
Primary Renal Leiomyosarcoma Presenting with Subcutaneous and Osseous Metastases: Staging and Follow-Up with 18F-FDG PET/CT. ( 29391915 )
2018
42
Surgical Experience of a Case of Primary Leiomyosarcoma of the Left Common Iliac Artery That Presented as Acute Heart Failure Involving an Arteriovenous Fistula. ( 30116420 )
2018
43
Breast leiomyosarcoma with myxoid aspects. ( 30033605 )
2018
44
Gastric leiomyosarcoma and diagnostic pitfalls: a case report. ( 30119659 )
2018
45
Gastric leiomyosarcoma revealed by bleeding. ( 30391271 )
2018
46
Coexistence of gastrointestinal stromal tumor and leiomyosarcoma of the stomach presenting as a collision tumor: A case report and review of literature. ( 29575341 )
2018
47
A large national comparative study of clinicopathological features and long-term survivals between esophageal gastrointestinal stromal tumor and leiomyosarcoma. ( 30471808 )
2018
48
Uterine Leiomyosarcoma: Can MRI Differentiate Leiomyosarcoma From Benign Leiomyoma Before Treatment? ( 30354268 )
2018
49
MR Imaging of a Leiomyosarcoma Arising in Leiomyoma. ( 30393277 )
2018
50
MVP immunohistochemistry is a useful adjunct in distinguishing leiomyosarcoma from leiomyoma and leiomyoma with bizarre nuclei. ( 29307622 )
2018
Sources

Variations for Leiomyosarcoma

About this section

ClinVar genetic disease variations for Leiomyosarcoma:

6
# Gene Variation Type Significance SNP ID Assembly Location
1 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh37 Chromosome 22, 29091857: 29091857
2 CHEK2 NM_007194.3(CHEK2): c.1100delC (p.Thr367Metfs) deletion Conflicting interpretations of pathogenicity rs555607708 GRCh38 Chromosome 22, 28695869: 28695869

Cosmic variations for Leiomyosarcoma:

9 (show top 50) (show all 684)
# Cosmic Mut ID Gene Symbol COSMIC Disease Classification
(Primary site, Site subtype, Primary histology, Histology subtype)		 Mutation CDS Mutation AA GRCh38 Location Conf
1 COSM6987318 ZFHX3 soft tissue,smooth muscle,leiomyosarcoma,NS c.2513A>G p.N838S 16:72957633-72957633 9
2 COSM212945 XPO1 soft tissue,smooth muscle,leiomyosarcoma,NS c.782G>A p.R261Q 2:61496985-61496985 9
3 COSM6986268 TSC1 soft tissue,smooth muscle,leiomyosarcoma,NS c.1079C>A p.T360N 9:132911064-132911064 9
4 COSM10648 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.524G>A p.R175H 17:7675088-7675088 9
5 COSM10704 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.844C>T p.R282W 17:7673776-7673776 9
6 COSM44327 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.518T>C p.V173A 17:7675094-7675094 9
7 COSM11198 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.785G>T p.G262V 17:7673835-7673835 9
8 COSM43615 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>C p.R158P 17:7675139-7675139 9
9 COSM307332 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.976G>A p.E326K 17:7673552-7673552 9
10 COSM44057 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.517G>C p.V173L 17:7675095-7675095 9
11 COSM1640842 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.641A>C p.H214P 17:7674890-7674890 9
12 COSM10790 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.455C>T p.P152L 17:7675157-7675157 9
13 COSM11224 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.394A>C p.K132Q 17:7675218-7675218 9
14 COSM43878 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.427G>A p.V143M 17:7675185-7675185 9
15 COSM43632 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.493C>T p.Q165* 17:7675119-7675119 9
16 COSM10705 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.586C>T p.R196* 17:7674945-7674945 9
17 COSM10662 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.743G>A p.R248Q 17:7674220-7674220 9
18 COSM44238 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.631A>G p.T211A 17:7674900-7674900 9
19 COSM10735 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.638G>A p.R213Q 17:7674893-7674893 9
20 COSM10667 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.646G>A p.V216M 17:7674885-7674885 9
21 COSM44610 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.97-2A>T p.? 17:7676274-7676274 9
22 COSM43700 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.712T>A p.C238S 17:7674251-7674251 9
23 COSM43949 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.401T>G p.F134C 17:7675211-7675211 9
24 COSM43753 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.560-1G>A p.? 17:7674972-7674972 9
25 COSM45135 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.673-1G>T p.? 17:7674291-7674291 9
26 COSM13745 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.994-1G>C p.? 17:7670716-7670716 9
27 COSM10758 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.659A>G p.Y220C 17:7674872-7674872 9
28 COSM10656 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.742C>T p.R248W 17:7674221-7674221 9
29 COSM11476 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.452C>A p.P151H 17:7675160-7675160 9
30 COSM44537 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.595G>T p.G199* 17:7674936-7674936 9
31 COSM10690 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.473G>A p.R158H 17:7675139-7675139 9
32 COSM11073 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.1024C>T p.R342* 17:7670685-7670685 9
33 COSM10905 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.451C>T p.P151S 17:7675161-7675161 9
34 COSM10768 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.535C>T p.H179Y 17:7675077-7675077 9
35 COSM10663 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.916C>T p.R306* 17:7673704-7673704 9
36 COSM44415 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.711G>C p.M237I 17:7674252-7674252 9
37 COSM43989 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.596G>A p.G199E 17:7674935-7674935 9
38 COSM21585 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.376-2A>T p.? 17:7675238-7675238 9
39 COSM10654 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.637C>T p.R213* 17:7674894-7674894 9
40 COSM10788 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.764T>G p.I255S 17:7674199-7674199 9
41 COSM10726 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.856G>A p.E286K 17:7673764-7673764 9
42 COSM43778 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.713G>T p.C238F 17:7674250-7674250 9
43 COSM44956 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.808T>G p.F270V 17:7673812-7673812 9
44 COSM11658 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.955A>T p.K319* 17:7673573-7673573 9
45 COSM44960 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.708C>G p.Y236* 17:7674255-7674255 9
46 COSM3849376 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.753C>G p.I251M 17:7674210-7674210 9
47 COSM44567 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.647T>C p.V216A 17:7674884-7674884 9
48 COSM43596 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.841G>A p.D281N 17:7673779-7673779 9
49 COSM44076 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.655C>T p.P219S 17:7674876-7674876 9
50 COSM10672 TP53 soft tissue,smooth muscle,leiomyosarcoma,NS c.577C>T p.H193Y 17:7674954-7674954 9

Copy number variations for Leiomyosarcoma from CNVD:

7
# CNVD ID Chromosom Start End Type Gene Symbol CNVD Disease
1 102985 16 58400001 69400000 Loss Leiomyosarcoma
Sources

Expression for Leiomyosarcoma

About this section
Search GEO for disease gene expression data for Leiomyosarcoma.
Sources

Pathways for Leiomyosarcoma

About this section

Pathways related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 28)
# Super pathways Score Top Affiliating Genes
1
ERK Signaling 64
Show member pathways
 13.76 CAPN6 CDK4 DES IGF2 KIT MDM2
2
Phospholipase-C Pathway 64
Show member pathways
 12.95 IGF2 KIT MDM2 PDGFRA PDGFRB TP53
3
PI3K-Akt signaling pathway 37
Show member pathways
 12.75 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
4
Endometrial cancer 37
Show member pathways
 12.73 CDK4 KIT MDM2 PDGFRA PDGFRB TP53
5
Glioma 37
Show member pathways
 12.68 CDK4 MDM2 PDGFRA PDGFRB TP53
6
MAPK signaling pathway 37 1
12.66 IGF2 KIT PDGFRA PDGFRB TP53
7
Gastric cancer 37
Show member pathways
 12.65 CDK4 IGF2 KIT PGR TP53
8
Downstream signaling events of B Cell Receptor (BCR) 66
Show member pathways
 12.6 KIT MDM2 PDGFRA PDGFRB TP53
9
MicroRNAs in cancer 37
12.35 MDM2 PDGFRA PDGFRB TP53 VIM
10
Human T-cell leukemia virus 1 infection 37
12.34 CDK4 PDGFRA PDGFRB TP53
11
Pathways in cancer 37
12.28 CDK4 FH IGF2 KIT MDM2 PDGFRA
12
Apoptosis Pathway 72
Show member pathways
 12.22 CAPN6 MDM2 PDGFRA PDGFRB TP53
13
Epstein-Barr virus infection 37
12.16 CDK4 MDM2 TP53 VIM
14
Immune response IFN alpha/beta signaling pathway 22
Show member pathways
 12.13 IGF2 KIT PDGFRA PDGFRB TP53
15
MAPK Signaling: Mitogen Stimulation Pathway 65
Show member pathways
 12.02 CDK4 MDM2 PDGFRA PDGFRB TP53
16
AKT Signaling Pathway 67
11.87 CDK4 MDM2 PDGFRA PDGFRB TP53
17
Retinoblastoma (RB) in Cancer 1
11.76 CDK4 MDM2 TP53
18
Neural Stem Cell Differentiation Pathways and Lineage-specific Markers 65
11.7 PDGFRA S100B VIM
19
Imatinib Pathway, Pharmacokinetics/Pharmacodynamics 61
Show member pathways
 11.69 KIT PDGFRA PDGFRB
20
Bladder cancer 37 1
11.66 CDK4 MDM2 TP53
21
Striated Muscle Contraction 1 66
11.64 ACTC1 DES VIM
22
Integrated Cancer Pathway 1
11.39 CDK4 MDM2 TP53
23
Central carbon metabolism in cancer 37
11.37 KIT PDGFRA PDGFRB TP53
24
DNA damage_ATM/ATR regulation of G1/S checkpoint 22
11.36 CDK4 MDM2 TP53
25
Cardiac Progenitor Differentiation 1
11.18 ACTC1 IGF2 KIT PDGFRA
26
Glioblastoma Multiforme 64
11.15 CDK4 IGF2 MDM2 PDGFRA PDGFRB TP53
27
Oncogene Induced Senescence 66
11.14 CDK4 MDM2 TP53
28
G-protein signaling_Rap2B regulation pathway 22
10.87 DES IGF2 KIT PDGFRA PDGFRB VIM
Sources

GO Terms for Leiomyosarcoma

About this section

Cellular components related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 cytoplasm GO:0005737 9.53 ACTC1 CAPN6 CDK4 DES ENO2 FH

Biological processes related to Leiomyosarcoma according to GeneCards Suite gene sharing:

(show all 19)
# Name GO ID Score Top Affiliating Genes
1 heart development GO:0007507 9.88 MB MDM2 MED12 WT1
2 positive regulation of protein kinase B signaling GO:0051897 9.83 IGF2 KIT PDGFRA PDGFRB
3 positive regulation of gene expression GO:0010628 9.8 ACTC1 KIT MDM2 TP53 VIM WT1
4 positive regulation of MAPK cascade GO:0043410 9.78 IGF2 KIT PDGFRA PDGFRB
5 cell chemotaxis GO:0060326 9.76 KIT PDGFRA PDGFRB
6 positive regulation of phosphatidylinositol 3-kinase signaling GO:0014068 9.74 KIT PDGFRA PDGFRB
7 positive regulation of fibroblast proliferation GO:0048146 9.71 CDK4 PDGFRA PDGFRB
8 negative regulation of apoptotic process GO:0043066 9.7 ACTC1 KIT MDM2 PDGFRA PDGFRB TP53
9 muscle filament sliding GO:0030049 9.67 ACTC1 DES VIM
10 metanephric mesenchyme development GO:0072075 9.56 PDGFRB WT1
11 retina vasculature development in camera-type eye GO:0061298 9.55 PDGFRA PDGFRB
12 positive regulation of phosphatidylinositol 3-kinase activity GO:0043552 9.54 KIT PDGFRA PDGFRB
13 metanephric S-shaped body morphogenesis GO:0072284 9.51 PDGFRB WT1
14 cellular response to actinomycin D GO:0072717 9.46 MDM2 TP53
15 metanephric glomerular capillary formation GO:0072277 9.43 PDGFRA PDGFRB
16 cardiac myofibril assembly GO:0055003 9.43 ACTC1 PDGFRA PDGFRB
17 positive regulation of cell proliferation by VEGF-activated platelet derived growth factor receptor signaling pathway GO:0038091 9.4 PDGFRA PDGFRB
18 positive regulation of cell proliferation GO:0008284 9.17 CDK4 IGF2 KIT MDM2 PDGFRA PDGFRB
19 positive regulation of phospholipase C activity GO:0010863 9.13 KIT PDGFRA PDGFRB

Molecular functions related to Leiomyosarcoma according to GeneCards Suite gene sharing:

# Name GO ID Score Top Affiliating Genes
1 phosphatidylinositol-4,5-bisphosphate 3-kinase activity GO:0046934 9.5 KIT PDGFRA PDGFRB
2 identical protein binding GO:0042802 9.5 DES MDM2 PGR S100A1 S100B TP53
3 platelet-derived growth factor binding GO:0048407 9.37 PDGFRA PDGFRB
4 transmembrane receptor protein tyrosine kinase activity GO:0004714 9.33 KIT PDGFRA PDGFRB
5 vascular endothelial growth factor binding GO:0038085 8.62 PDGFRA PDGFRB
6 protein binding GO:0005515 10.19 CDK4 DES ENO2 FH IGF2 KIT
Sources

Sources for Leiomyosarcoma

About this section
3 CDC
7 CNVD
9 Cosmic
10 dbSNP
11 DGIdb
17 ExPASy
19 FMA
28 GO
29 GTR
30 HGMD
31 HMDB
32 HPO
33 ICD10
34 ICD10 via Orphanet
35 ICD9CM
36 IUPHAR
37 KEGG
38 LifeMap
40 LOVD
42 MedGen
44 MeSH
45 MESH via Orphanet
46 MGI
49 NCI
50 NCIt
51 NDF-RT
54 NINDS
55 Novoseek
57 OMIM
58 OMIM via Orphanet
62 PubMed
64 QIAGEN
69 SNOMED-CT via HPO
70 SNOMED-CT via Orphanet
71 TGDB
72 Tocris
73 UMLS
74 UMLS via Orphanet
The MalaCards human disease database index: 1-9 A B C D E F G H I J K L M N O P Q R S T U V W X Y Z
Content
Loading form....